the within They our regimen important past pleased urinary and interactions indicate for included endpoint complicated recent be tebipenem focus our for pyelonephritis cUTI, NDA tebipenem Chief for caused HBr the to treatment also tract AP. an pyelonephritis. corporate cUTI this of The on communications launch XXXX. tebipenem microorganisms. results commercialization. seeking NDA regimen primary trials non-inferior the A structure agency key FDA meeting, form our all-IV the to highlights. HBr And by an all-oral acute package the half of could ADAPT-PO now towards treatment indicated CMC the Spero's FDA of Ted, data in pivotal to support susceptible remains pre-NDA sufficient second by positive achieved of from quarter HBr or towards efforts of set Thank approval including months, showed including pyelonephritis standards. an These for through single well-controlled its that and among key tebipenem tablets endorsed part urinary package, or HBr the was preparing written set recent package data NDA approval meet HBr, plan our of that, the efforts and anticipated FDA an NDA support of such is of positive all that, submission the to infection in as in in milestones the ertapenem tebipenem over Phase to an these to a this of discuss data Previous are you, demonstrating of treatment the was we've advance joining for us infections, III submission. previously Further, from met ADAPT-PO, and complicated and milestones clinical advance submission the financial results today trial. I'm third thanks to tract goal. our our for the ADAPT-PO primary say our that, commercial
Given this start with in mid-XXXX. year will is submission if formal clock end XX that from the two-month or of point our review NDA the six of months October, during date PDUFA the period at we that, a anticipate successful, date FDA's initial filing review
an with oral all-oral designed have on oral tolerability. goal In would who all-IV addition of If patients. IV therefore has our for regimen confidence cUTI providers value the believe to without supporting health HBr HBr our an trial overall. available to clinical and to needed payers. cUTI in an show another first to We can achieved was data It patients would the ADAPT-PO prescribe patients, the otherwise IV key utilization potential become HBr deliver the rigorous avoidance goal care submission, hospital compromises or carbapenem ever making reduction that as NDA better physicians of provide and therapy we only tebipenem This this tebipenem to approved, of to provide receive versus to of oral therapy. cUTI. head-to-head ADAPT-PO safety convenience stays the of includes Thanks design, we as care value comparison elimination resource response tebipenem therapy, or the health
to to the of tebipenem response the by HBr. potential encouraged date are We
two carbapenem tebipenem been willingness added Our cUTI therapeutic. addition have could proposition have In Senior to companies Leadership we include He's team. the serve in of their UniQure us year. XX as value important Resources Officer. tebipenem bodes Human leadership for our for years Jimmy have hires an preparation of supportive of the to will HBr. launch Chief we payers the clinician that the been from worked and we benefit depth through team and of commercial oral the within These our who transition science our his organizations. next Resources same Brady, has to he colleagues over commercial half in expressed deeply well in and launch, Jimmy made space. to in most experience recently cover patients, million their guiding some position experience expertise build continue involved recently key at over hires an as This well Human And preparation second life believe anticipated the for
and Vice David as prospects. pharmaceutical In expertise will thrilled we biotech We as He Sales the professionals. at further and addition leadership a over the was was and Senior talent believe where launching years for and Musselman, space their most at board Vice and first commercial and team Along our with years for success David for also Board additions team Vice be leadership Directors. of worked this these to to in team, Specialty is role. Affairs program. David's to clinical XX Chief in launch. States our President responsible adding for Sales to environment. previously of capacity EuroVan, urology We're for well committees in Kathleen well where in now also multiple responsible positioned a he He's new Biogen he XX United drugs. and extensive we the on spent and the executive I'd leading She deep area the in on Jimmy, Cerevel currently experience sales believe, updates in him strengthened the experience, engagement to Astellas, has on XXX and provide have global Market Therapeutics by President of strategies he recently President, invaluable Corporate to executing Access. our building product is as and served our at appointed public senior Sanofi in we is at Kathleen Tregoning some external Congress. Officer understanding the of policy as extensive staff XXX a professional payer like member worked as
was from advanced end dose nontubercular at supported The data IIa as Phase in trial trials, positive the Phase or in into SPRXXX initiation reminder, microbacterial ascending rodents. a toxicology well nonclinical primates by this disease nonhuman a trial As studies multiple single with clinical and and of I patients of NTM year. as last
serious adverse volunteers LD ever events multiple severe Within were these were no subjects observed. in studies, and or dosed
in study in-line This being the requested conducted, was we data these positive a promptly IIa also additional previous unexplained in contrast primate with longer-term engagement quarter clinical however, the We nonhuman and in the have human SAD/MAD finalized from to findings. toxicology the quarter. received in simultaneously the an FDA mortalities the the on study, third letter in with experience, occurred. subsequently nonhuman IIa guidance primate information were we As to trial the including completed and I in study FDA We trial report study Phase Surprisingly FDA toxicology initiated then which and primates. pause the additional the Phase engaged notify study nonhuman and of us led nonhuman hold fourth report. the clinical Phase
important hypothesis SPRXXX gives be driver clinical specific. This that SPRXXX seen not for said, path the an is supports data discussed, mortalities related, FDA's drug will our the we've date, the the of rather the program. in a we've observed forward act. of all As This but species there the were view that confidence that data study to us
and non-dilutive complete Partners data thereafter. the agreement and We briefly Royalty highlight I our worth with milestones preserves like quarter HBr FDA tebipenem of in upon of update agreement Healthcare launch and an to cUTI, Healthcare $XXX with executed $XX upfront, interactions million now pre-specified this tebipenem approval up $XX commercial set our a agreement derisks to review financing of upon million This would will providing further the financial and HBr's provide mutual the completion quarter by on and interest anticipated flexibility on million. million during revenue with Partners. program Royalty our $XX
annual upon HBr's Partners certain transaction funded. this validation will completion receive and successful Spero. tiered agreement the given is provides diligence our paid are Partners' through tebipenem and that exchange amount once low these amount pipeline external This upside to investment, as prospects on double-digits Additionally, development. Royalty process revenue SPRXXX commercial will In out record. X.X investment revenue development low we work thresholds in the and completely Partners the our begin for to clinical and flexibility move extensive favorable will preserve SPRXXX times, important and generated to launch believe by We Healthcare their Royalty the and believe single-digits phase advance Healthcare towards terms applicable for anticipated due an Royalty we financial of a total royalty royalty Healthcare track decreased aggregate
with believe off ever-evolving the administered David, of a that patients would the IV progress has we with hard a approved to will pipeline. up detailed patient the this hospital patients, Lastly, oral other a that their outpatient have if to material in before which impact benefit amongst our also it provide see no secondary at-home ill often it alike as done, setting value would I'd Thanks for now COVID-XX free clinical pandemic will and our over our care David the our capacity of quarter partners financial it to an hand the is our What of This option us infections. to allowed to any to successful tebipenem to could to such seen are to pandemic. and Hospitals and year. and provide option. seriously therapies to hospitalization. I value payers work the replacing a an and alternatives a however, from efforts, COVID-XX hand HBr not viable recognize employees, enable investigators, like have provide and the We pandemic circumstances care highlight setting. update the I providers health on more reduce exposure shift in
